- Who are the top players of the market and growth strategies.
- Precision Medicine Software Market Growth Factors.
- Leading Segments.
Global market size-
According to the report precision medicine software market is projected to reach $2.0 billion by 2024 from $1.2 billion in 2019, at a CAGR of 11.5%.
For Details, Download PDF Brochure Here
Top players & growth strategies –
2bPrecise has a strong foothold in the precision medicine software market. The company caters to the healthcare technology and precision medicine needs of its global customers. 2bPrecise focuses on agreements and collaborations to expand its business operations.
In 2018, Foundation Medicine was one of the leading providers in the precision medicine software market. In order to maintain its leading position in the market, the company focuses on several partnerships with government and private institutes. For example, during 2016–2018, the company partnered with various healthcare organizations in the US.In 2018, Syapse was among the key players in the precision medicine software market. The company focuses on partnerships and collaborations to expand its business operations. The company also offers qualitative software tools by adopting advanced technologies.
Market growth influenced due to following factors-
· Partnerships among pharmaceutical and software companies.
· Rising government funding in precision medicine initiatives.
· Growth in the number of cancer patients.
· Cloud-based solutions and artificial intelligence in precision medicine may act as an important boosting factor for the exponential growth of the market.
Top Segment -•Based on applications, the precision medicine software market is segmented into oncology, pharmacogenomics, rare diseases, and other applications.•On the basis of delivery mode, the precision medicine software market is segmented into on-premise and cloud-based delivery model.•By end user, the market is segmented into healthcare providers, research centers& government institutes, pharmaceutical & biotechnology companies, and other end users.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.